Belly Fat and Blood Sugar Together May Blunt Thyroid Hormone Sensitivity in Diabetes

For millions of people living with type 2 diabetes, the thyroid gland has long been treated as a separate concern, checked once a year and largely ignored unless the numbers drift out of range. A new study from China suggests that the two systems are far more entangled than routine care assumes. Researchers report that a single composite measure, combining insulin resistance with visceral fat accumulation, tracks closely with how sensitively the body’s tissues respond to thyroid hormone. The finding, drawn from one of the larger cross-sectional datasets assembled on this question, adds weight to a growing view that metabolic dysfunction and thyroid physiology are not parallel stories but a single, interwoven one.

The study, published in BMC Endocrine Disorders, recruited 7,023 adults with type 2 diabetes mellitus from two medical centers in China between June 2020 and August 2025. Its central tool was the triglyceride-glucose-Chinese visceral adiposity index, abbreviated TyG-CVAI, a calculated composite that merges two established markers of metabolic risk. The first component, the triglyceride-glucose index, is a simple arithmetic transformation of fasting triglyceride and glucose concentrations that serves as a widely validated proxy for insulin resistance. The second, the Chinese visceral adiposity index, integrates age, sex, body mass index, waist circumference, triglycerides and high-density lipoprotein cholesterol into a score that estimates the burden of fat packed around internal organs, the metabolically aggressive depot most strongly linked to cardiovascular and endocrine disease.

By multiplying these two risk dimensions into one index, the investigators created what they describe as a joint signature of obesity and insulin resistance. The logic is straightforward: neither insulin resistance nor visceral adiposity alone captures the full metabolic picture, and patients who carry both tend to fare worst across a range of outcomes. What remained unclear before this study was whether that combined burden also extends to the thyroid axis, specifically to what endocrinologists call thyroid hormone sensitivity, the efficiency with which circulating thyroid hormones feed back to the brain and act on peripheral tissues.

Thyroid hormone sensitivity is notoriously difficult to measure directly. Instead, researchers rely on composite laboratory indicators derived from routine thyroid function tests. The study employed four of them. The thyroid feedback quantile index, or TFQI, compares an individual’s free T4 level against the population distribution while factoring in thyroid-stimulating hormone, yielding a population-normalized measure of how well the hypothalamic-pituitary-thyroid feedback loop is calibrated. The thyroid-stimulating hormone index, or TSHI, and the thyrotroph T4 resistance index, or TT4RI, quantify how much the pituitary has to be driven, or how much T4 is circulating, to maintain a given TSH level, with higher values suggesting the brain and body are resisting the hormone’s signal. The ratio of free triiodothyronine to free thyroxine, FT3/FT4, offers a peripheral window into how readily T4 is converted into the more active T3.

The results were consistent across the main sensitivity markers. In fully adjusted multivariable linear regression models that accounted for demographic, lifestyle and clinical confounders, each one-standard-deviation increase in TyG-CVAI was significantly associated with an elevated TFQI, with a beta coefficient of 0.01 and a 95 percent confidence interval of 0.00 to 0.02, reaching a p-value of 0.019. The same pattern held for TSHI, which rose by 0.07 per standard deviation of the composite index, with a confidence interval of 0.02 to 0.12 and a p-value of 0.005. The strongest signal appeared for TT4RI, which climbed by 3.06 points per standard deviation increase, with a confidence interval of 2.07 to 4.05 and a p-value below 0.001. Higher TFQI, TSHI and TT4RI values all point in the same direction: reduced sensitivity to thyroid hormone, meaning the pituitary must work harder, and more hormone circulates, to achieve the same biological effect.

The researchers also stratified participants into tertiles, or thirds, of TyG-CVAI. Those in the highest third showed markedly greater increases in the sensitivity indices compared with those in the lowest third. For TT4RI, the difference between the top and bottom tertiles was a beta of 6.30, with a confidence interval of 3.90 to 8.70 and a p-value below 0.001, a substantial gap for an index derived from routine blood work. The graded relationship across tertiles strengthens the biological plausibility of the association, because a dose-response pattern is harder to explain by chance or confounding than a simple binary difference.

Two subgroup findings deserve particular attention. The associations were more pronounced in women and in patients with a shorter duration of diabetes. The sex difference echoes a broader literature in which thyroid disorders disproportionately affect women and in which adiposity-related endocrine disruption appears to follow sexually dimorphic pathways. The finding that recently diagnosed patients show the strongest link suggests that the metabolic-thyroid coupling may be most visible early in the disease course, before long-standing diabetes, medication effects and age-related changes muddy the physiological waters. If confirmed, that could make the composite index most useful precisely at the stage when clinicians are deciding how aggressively to intervene on weight and glucose control.

The study’s design imposes important limits on interpretation. As a cross-sectional analysis, it captures a single moment in time and cannot establish whether higher TyG-CVAI causes reduced thyroid hormone sensitivity, whether impaired thyroid action promotes visceral fat and insulin resistance, or whether both arise from shared upstream drivers such as inflammation, altered fat metabolism or mitochondrial dysfunction. Reverse causation is a genuine possibility, since thyroid hormone is itself a major regulator of lipolysis, gluconeogenesis and resting energy expenditure, and reduced hormone sensitivity could plausibly feed back into the very metabolic derangements the index measures. The authors note that the associations were robust in sensitivity analyses, but only longitudinal cohorts and mechanistic studies can settle the direction of the arrow.

Even so, the clinical implications are tantalizing. The TyG-CVAI requires nothing beyond a standard metabolic panel and anthropometric measurements, making it cheap and reproducible in almost any clinic. If the index genuinely flags patients whose tissues are becoming resistant to thyroid hormone, it could help identify people with type 2 diabetes who warrant closer thyroid monitoring, or conversely, it could serve as a motivational metric, a single number that improves as patients lose visceral fat and regain insulin sensitivity, with thyroid physiology improving in parallel. The concept of thyroid hormone resistance is also attracting renewed interest in metabolic research, with some investigators proposing that impaired peripheral conversion and action of thyroid hormone may be an adaptive response to overnutrition rather than a primary defect, a hypothesis this study’s correlational data can neither confirm nor refute.

What the study does establish is a clear and quantifiable association in a large, well-characterized population: in adults with type 2 diabetes, the combined burden of insulin resistance and visceral adiposity, as captured by TyG-CVAI, rises in lockstep with laboratory markers of diminished thyroid hormone sensitivity. The work was conducted under the Declaration of Helsinki with ethical approval from both participating hospitals, and all participants provided written informed consent. The research was supported by the Science and Technology Plan Project of Taizhou and the National Natural Science Foundation of China. Whether the relationship proves causal or merely correlational, the message for patients and clinicians is the same: the metabolic and thyroid axes are talking to each other, and the conversation is loudest in those carrying the most visceral fat and the deepest insulin resistance.

Subject of Research: Association between a combined insulin resistance and visceral adiposity index and thyroid hormone sensitivity in type 2 diabetes

Article Title: Association of the triglyceride glucose-Chinese visceral adiposity index with thyroid hormone sensitivity in patients with type 2 diabetes

Article References: Liu, Y., Cai, N., Huang, R., Pan, Y., Chen, M., Feng, P., Song, Y., Zheng, C., & Chen, M. (2026). Association of the triglyceride glucose-Chinese visceral adiposity index with thyroid hormone sensitivity in patients with type 2 diabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02562-x

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02562-x

Keywords: type 2 diabetes, insulin resistance, visceral adiposity, TyG-CVAI, thyroid hormone sensitivity, TFQI, TSHI, TT4RI, cross-sectional study, endocrinology, metabolic syndrome, thyroid function